Affiliation:
1. V. I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation
Abstract
Today cardiovascular diseases and oncopathology are leading causes in the structure of mortality worldwide. The complexity of diagnostics of haemocoagulation complications in this comorbid pathology remains an urgent problem at present. The aim of our study was to investigate the mechanisms of thrombotic readiness state formation using the thrombodynamics test on the example of patients with cardiovascular diseases (CHD, arterial hypertension) and aggravated oncoanamnesis depending on the activity of oncoprocess. The study was conducted in 100 patients aged 37 – 86 years: 60 patients with active oncoprocess (group 1) and 40 patients with oncoprocess in remission (group 2). Clinical, anamnestic and laboratory data were studied using a statistical analysis. The main attention was paid to the thrombodynamics test indicators (both velocity and structural). It was found that the most informative indicators of the haemostasis system state estimation in patients with cardiovascular pathology and aggravated oncoanamnesis depending on the oncoprocess activity are thrombodynamic indices both velocity and structural. Almost half of cardiological patients with an aggravated oncoanamnesis had a state of thrombotic readiness irrespective of the activity of the oncological process. These indices were higher in active oncopathology than in oncopathology in remission. At the same time no differences in the data of standard coagulogram in both groups could be revealed. Application of thrombodynamics test in cardiological patients with oncoanamnesis allows to reveal the states of thrombotic readiness and to establish the degree of influence of oncoprocess activity on the formation of this state, which demonstrates fundamentally new aspects of diagnostics of procoagulant states in patients of this profile.
Publisher
North-Eastern Federal University
Reference18 articles.
1. Kryuchkova O.N., Perminov A.A., Itskova E.A. et al. The problem of cardiotoxicity in patients receiving therapy for malignant neoplasms. modern approaches to risk stratification, diagnosis and treatment // Crimean Therapeutic Journal 2022; No. 3: 19 – 25. URL: https://cyberleninka.ru/article/n/problema-kardiotoksichnosti-upatsientov-poluchayuschih-terapiyu-zlokachestvennyh-novoobrazovaniy-sovremennye-podhody-k.
2. Fernandes C.J., Morinaga L.T.K., Alves J.L.Jr et al. Cancer-associated thrombosis: the when, how and why // European Respiratory Review 2019; 28 (151): 180119. doi: 10.1183/16000617.0119-2018.
3. Ataullakhanov F.I., Rumyantsev A.G. New ideas about blood coagulation // Russian Journal of Paediatric Haematology and Oncology 2018; No. 3: 13 – 22. URL: https://cyberleninka.ru/article/n/novye-predstavleniyao-svertyvanii-krovi.
4. Johnson C.B., Davis M.K., Law A. et al. Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients. Canadian Journal of Cardiology Elsevier 2016; 32: 900 – 907. doi: 10.1016/j.cjca.2016.04.008.
5. Manolis A.A., Manolis T.A., Mikhailidis D.P. et al. Cardiovascular safety of oncologic agents: a doubleedged sword even in the era of targeted therapies – Part 2 // Expert Opinion on Drug Safety 2018; 17(9): 893 – 915. doi: 10.1080/14740338.2018.1513489.